AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
vTv Therapeutics Inc. Class A Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG009DT9XK8
25.55▼ 1.61 (-5.93%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
27.16
Day's Range
25.35 – 27.31
52-Week Range
19.50 – 44.39
Volume
21.5K
Avg Volume
31.7K
Share Statistics
Shares Outstanding
Employees
26
Exchange
XNAS
Listed
2015-07-30
Share count as of August 6, 2026

vTv Therapeutics Inc. Class A Common Stock (VTVT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about vTv Therapeutics Inc. Class A Common Stock (VTVT)
What is vTv Therapeutics Inc. Class A Common Stock's Market Cap?
vTv Therapeutics Inc. Class A Common Stock's Market Cap is $101.0M, based on as-reported figures from SEC (XBRL) filings.
What is vTv Therapeutics Inc. Class A Common Stock's Price / Sales?
vTv Therapeutics Inc. Class A Common Stock's Price / Sales is 2.7×, based on as-reported figures from SEC (XBRL) filings.
What is vTv Therapeutics Inc. Class A Common Stock's Revenue (TTM)?
vTv Therapeutics Inc. Class A Common Stock's Revenue (TTM) is $36.8M, based on as-reported figures from SEC (XBRL) filings.
What is vTv Therapeutics Inc. Class A Common Stock's Net Income (TTM)?
vTv Therapeutics Inc. Class A Common Stock's Net Income (TTM) is -$4.8M, based on as-reported figures from SEC (XBRL) filings.
What is vTv Therapeutics Inc. Class A Common Stock's EBITDA?
vTv Therapeutics Inc. Class A Common Stock's EBITDA is -$9.2M, based on as-reported figures from SEC (XBRL) filings.
What is vTv Therapeutics Inc. Class A Common Stock's Diluted EPS (TTM)?
vTv Therapeutics Inc. Class A Common Stock's Diluted EPS (TTM) is -1.20, based on as-reported figures from SEC (XBRL) filings.
What is vTv Therapeutics Inc. Class A Common Stock's EBITDA Margin?
vTv Therapeutics Inc. Class A Common Stock's EBITDA Margin is -25.1%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · VTVTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth——-100.0%—
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue—36.9%——
Operating (loss) income
% of revenue—63.1%——
Other income (expense), net————
Interest income
Net (loss) income before income taxes and noncontrolling interest
Income tax provision
Net (loss) income before noncontrolling interest
% of revenue—65.5%——
Less: net loss attributable to noncontrolling interest
Net (loss) income attributable to vTv Therapeutics Inc.
% of revenue—65.5%——
Net (loss) income attributable to vTv Therapeutics Inc. common shareholders
Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)
Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock (in usd per share)